The significant clinical differences observed between the genetic subgroups (such as the early onset of disease and greater number of disease features in DKC1 and TINF2 patients compared to TERC and TERT patients and the higher incidence of cancer in patients with TERC mutations) will facilitate more informed decisions in the clinic. This evidence concerns the gene TERC and cancer.